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Abstract
Background: Currently, the PDB contains approximately 29,000 protein structures comprising
over 70,000 experimentally determined three-dimensional structures of over 5,000 different low
molecular weight compounds. Information about these PDB ligands can be very helpful in the field
of molecular modelling and prediction, particularly for the prediction of protein binding sites and
function.
Description: Here we present an Internet accessible database delivering PDB ligands in the MDL
Mol file format which, in contrast to the PDB format, includes information about bond types.
Structural similarity of the compounds can be detected by calculation of Tanimoto coefficients and
by three-dimensional superposition. Topological similarity of PDB ligands to known drugs can be
assessed via Tanimoto coefficients.
Conclusion: SuperLigands supplements the set of existing resources of information about small
molecules bound to PDB structures. Allowing for three-dimensional comparison of the compounds
as a novel feature, this database represents a valuable means of analysis and prediction in the field
of biological and medical research.
Background
Protein modelling and structure prediction as well as
binding and interaction prediction have become very val-
uable instruments for researchers in biology and medi-
cine. In order to build reasonable and useful models, as
much information as possible has to be incorporated into
the protein modelling process. To refine protein models,
chemical as well as spatial information about ligand struc-
tures can be considered, specifically to optimise side-
chain conformations around binding-sites [1].
Several databases delivering structures and different addi-
tional information about ligand molecules from the Pro-
tein Data Bank (PDB) [2], [21] have been provided on the
Internet. Ligand Depot [3], [22] comprises chemical and
structural information for small molecules found in the
PDB and also provides a graphical interface for perform-
ing chemical substructure searches. Idealized three-
dimensional structures and additional information about
PDB ligands can be retrieved via the search interface of the
E-MSD macromolecular structure relational database [4],
[23]. Besides many other features, Relibase [5], [24]
allows for two-dimensional similarity and substructure
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search among the ligands as well as for sequence similar-
ity search among the corresponding proteins. LigBase [6],
[25] is a database of ligand binding sites aligned with
related protein structures and sequences. Various infor-
mation about ligands bound to macromolecules depos-
ited in the PDB can be retrieved from many further
sources like HIC-Up [7], [26], PDBsum [8], [27] and the
IMB Jena Image Library of Biological Macromolecules [9],
[28]. The latter can be searched after geometrical proper-
ties of the ligand binding sites.
Information contained in these databases can help identi-
fying ligands which are likely to bind to a given protein
structure. The opposite question, namely to find target
proteins for a certain ligand, was addressed in [10], where
a collection of protein active sites was extracted from the
PDB and scanned with aid of a docking algorithm. Further
data collections emphasize the link between binding
affinities and structures of the protein-ligand complexes
and, inter alia, provide experimentally measured binding
data, e.g. PLD [11], [29] LPDB [12], [30], PDBbind [13],
[31].
For modelling and simulation purposes, chemical and
spatial information about protein ligands is vitally impor-
tant. Addressing this fact, SuperLigands is a collection of
small molecule structures contained in the PDB, facilitat-
ing comparison of the molecules regarding their two-
dimensional similarity. As spatial comparison of com-
pounds can deliver valuable information in addition to
this,  SuperLigands  also allows for three-dimensional
superpositions. Spatial coordinates of the compounds can
be retrieved as MDL Mol files, which include information
about multiple bonds.
Construction and content
Native conformations of small molecules contained in the
PDB and additional information were collected from the
PDB [2], [21], Ligand Depot [3], [22] and MSD [4], [23]
and deposited in the database SuperLigands. The database
has been designed as a MySQL relational database and
supplemented with a user-friendly web interface. Data-
base queries are performed and HTML pages are generated
via PHP scripts. The freely available MDL® Chime plug-in
is used to display molecules and allows the user some
manipulations of the view and to store the displayed mol-
ecule in the MDL Mol file format.
In order to enable fast two-dimensional searches, 960 bit
binary fingerprints (MDL MACCS Keys [14]) were calcu-
lated and stored in the database for all ligands. Tanimoto
coefficients are calculated via a PHP script. Here, all 960
MDL keys are included and equally weighted. The Tanim-
oto coefficient for two structures a and b is defined as fol-
lows: T(a,b)=Nab/(Na+Nb-Nab), where Na and Nb are
the numbers of bits set in the fingerprint of structure a and
b, respectively, and Nab is the number of bits which are
common to both fingerprints.
Three-dimensional superposition of two different PDB
ligands is performed in the following way: each confor-
mation of one molecule occurring in the PDB is super-
posed with each conformation of the second molecule.
Those two instances matching best are displayed. The best
match is defined by maximizing the score defined by
where RMSD is the Root Mean Square Deviation of the
superposed atoms. For completion, PDB codes, chain
identifiers and positions in the PDB files of the matched
conformations as well as the atom numbers of both lig-
ands, the number of superposed atoms, the number of
superposed atoms of the same type and the RMSD of the
superposition are returned. For detailed information
regarding the superposition algorithm see [15].
Utility
SuperLigands can be searched by hetero-ID (i.e. the three-
letter PDB code for hetero-compounds), name, molecular
formula or PDB identifier. In the results table, hetero-ID
and names of the compounds are given. Moreover, the
molecular structure is displayed in one cell of the table
where it can be rotated by the user and different display-
ing options can be chosen. More information like molec-
ular formula, atom numbers and occurrence in the PDB
can be retrieved additionally.
The database SuperLigands contains compounds defined
by 'HETATM' records in PDB files. Some of these mole-
cules may be bound to pseudopeptides but can also be
separate ligands. Coming across such a molecule, the user
is given a hint and is provided with a list of pseudopep-
tides in which this molecule is bound.
The user can search the database for molecules that have a
significant two-dimensional similarity to a given ligand or
assess the three-dimensional similarity of two com-
pounds by superposing them with each other. Such simi-
larity queries can be performed starting from the search
results tables or directly using separate forms. Using such
a form, the Tanimoto coefficient of two given structures
can also be retrieved.
A typical example for a query to SuperLigands is a search
for tobramycin, known as antiinfective and antibacterial
drug, starting in the main form. Searching the database for
similar compounds in the next step supplies the drug kan-
amycin as PDB ligand with the highest Tanimoto
score
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similarity (98.6%). Now, a three-dimensional superposi-
tion of all instances of tobramycin (32 atoms, two
instances) and kanamycin (33 atoms, four instances)
occurring in the PDB can be performed. The best fitting
structures are superposed and then displayed. In this case,
best fitting are the instances of tobramycin in PDB entry
1m4d and kanamycin in 1m4i with an RMSD of 0.14Å
(32 atoms superposed). Navigating through the website,
the topological and spatial similarities of PDB ligands can
be obtained easily. For example, tobramycin and ribos-
tamycin (31 atoms, four instances) have a Tanimoto coef-
ficient of 96.5%, the RMSD of their best superposition is
only 0.95Å (25 atoms superposed). In turn, geneticin (34
atoms, five instances) delivers a Tanimoto coefficient of
only 81.1% and a much better RMSD (0.16Å, 30 atoms
superposed).
As an additional feature of SuperLigands, similarity of PDB
ligands to known drugs can be assessed in a comfortable
manner. Starting with a ligand, a two-dimensional simi-
larity search as described above can be initiated, not only
among the PDB ligands but also in a database containing
the structures of known drugs (SuperDrug Database [16],
[32]). The drug structures found can be superposed spa-
tially (for an example, see Figure 1).
Discussion
Statistics: comparison of PDB ligands with drugs
Recently, a database containing 2396 drug molecules and
having the same design as SuperLigands has been created
(SuperDrug Database [16], [32]). To answer the question,
how many drugs or drug-like molecules are bound to PDB
structures, Tanimoto coefficients have been calculated for
all pairwise combinations of molecules from SuperLigands
and the SuperDrug Database. A set of 5,040 PDB ligands
has been incorporated into these calculations. Consider-
ing two molecules having a Tanimoto coefficient of 100%
(or greater than 95% ; 90%) identical or very similar, this
analysis reveals that 413 (771 ; 1,457) of 5,040 PDB lig-
ands are drugs or drug-like compounds.
Furthermore, some chemical properties of PDB ligands
and drugs have been compared (see Figure 2). The distri-
butions of numbers of hydrogen bond donors for PDB lig-
ands and drugs differ most significantly. A bigger
percentage of the drugs (26%) have no hydrogen bond
donor, the largest fraction of the PDB ligands (19%) have
two of them. About half of the drugs have no or only one
hydrogen bond donor, which applies for only a quarter of
the PDB ligands. About one third of the drugs have three
or four hydrogen bond acceptors, the fractions of drugs
with nine or more hydrogen bond acceptors drop below
3%. For the PDB ligands, the distribution is more flat:
only 22% of them have three or four hydrogen bond
acceptors, still over 3% of them have 11 hydrogen bond
acceptors. Most drugs have a logP value around 3, and the
logP values of the PDB ligands accumulate around the
negative value -1. Approximately the same fraction of PDB
ligands and drugs are "drug-like" according to the Lipinski
"Rule of five" [17]: 92 and 91%, respectively, have a logP
value less than 5, although altogether the logP values of
the drugs are closer to this critical value. A majority of the
PDB ligands have very low molecular weights in compar-
ison to the drugs, which supposedly is be caused by the
fact that in proteins often very small solvent molecules are
bound. Nevertheless, slightly more (5%) drugs than PDB
ligands fulfil the Lipinski "Rule of five" regarding the
molecular weight. The same applies for the numbers of
hydrogen bond donors (and acceptors): 7% (5%) more
drugs fulfil the Lipinski "Rule of five".
Compounds violating more than one of the Lipinski
Rules are assumed to have problems with bioavailability
and are therefore presumably not suitable as drugs. Table
1 shows the percentages of PDB ligands and drugs violat-
ing the Lipinski Rules. From this table can be seen that a
total of approximately 19% of the PDB ligands and 10%
of the drugs, respectively, violate more than one of the
Lipinski Rules. This analysis reveals that there are only
marginal differences between PDB ligands and drugs
regarding single chemical properties. But, not surpris-
ingly, from a general point of view, PDB ligands are signif-
icantly less drug-like than drugs.
Discussion
SuperLigands is a collection of PDB ligands freely accessi-
ble via a user-friendly web site. Molecular coordinates can
be retrieved as MDL Mol files, supplementing the connec-
tivity records contained in PDB files with bond types,
which are necessary for modelling and simulation pur-
poses. The database can be searched for compounds sim-
ilar to a given ligand by comparison of Tanimoto
coefficients. As stated in [15] and shown in the example in
the section Utility, spatial comparison of small molecules
can reveal more similarities, and thus similar kinds of
interaction, than a pure two-dimensional topology com-
parison. With aid of SuperLigands, such three-dimensional
comparisons can be performed easily. Moreover, the top-
ological similarity of PDB ligand structures to known
drugs can be assessed by calculation of Tanimoto
coefficients.
Conclusion
The database presented here supplements the set of exist-
ing resources of information about small molecules
bound to PDB structures. As novel features, three-dimen-
sional comparison of molecules as well as topology com-
parison of PDB ligands with known drugs are made
possible. Thus, SuperLigands represents a valuable meansBMC Bioinformatics 2005, 6:122 http://www.biomedcentral.com/1471-2105/6/122
Page 4 of 6
(page number not for citation purposes)
Usage of the web interface of SuperLigands Figure 1
Usage of the web interface of SuperLigands. From the main menu, the form Compound search can be reached. Here, a 
PDB ligand can be searched after hetero-ID, name, molecular formula or PDB identifier. In the first column of the results table, 
two buttons can be found to retrieve more information. The FULL info button delivers detailed information about the selected 
PDB ligand like molecular formula, atom numbers and occurrence in the PDB. After clicking the DRUGS button, a two-dimen-
sional similarity search among the drugs in the SuperDrug database [16] is performed. The best hits are displayed in a new win-
dow. From here, they can be spatially superposed. In the figure, this procedure was carried out for celecoxib, a COX-2 
inhibitor which was recently categorised as problematic (see the "Pfizer Statement on New Information Regarding Cardiovas-
cular Safety of Celebrex" [18]). The two-dimensional similarity search in the SuperDrug database delivers only hits below 72% 
Tanimoto similarity. A following spatial superposition of the best hits reveals a further COX-2 inhibitor, namely valdecoxib, 
(RMSD 0.26Å and 21 of 22 atoms superposed) as very similar to celecoxib. The Tanimoto similarity of celecoxib and val-
decoxib is only 65% and there are two drugs more similar to celecoxib: Sulfaphenazole (71% Tanimoto similarity, spatial super-
position with 0.65Å RMSD and 15 of 22 atoms superposed) and Sulfamazone (67% Tanimoto similarity, spatial superposition 
with 0.32Å RMSD and 17 of 26 atoms superposed). Nevertheless, the three-dimensional comparison here proves to be very 
important to reveal molecular similarities in addition to topological comparison (as also shown in the example in the section 
Utility), which is confirmed by the fact that valdecoxib was categorised as toxic [19] and sales of this drug were suspended 
recently [20].BMC Bioinformatics 2005, 6:122 http://www.biomedcentral.com/1471-2105/6/122
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of analysis and prediction in the field of biological and
medical research.
Availability and requirements
The database is publicly accessible at http://bioinf.char
ite.de/superligands/. For visualisation, the free browser
plug-in MDL® Chime is required. Chime runs on Win-
dows systems with Microsoft Internet Explorer (6.0 or 5.5
SP2) or Netscape 4.75, 4.79 or on Mac OS 9.0 or 8.6 with
Netscape 4.75 (please see http://www.mdlchime.com/
products/framework/chime/sys_req.jsp for detailed
information).
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Statistics: comparison of PDB ligands with drugs Figure 2
Statistics: comparison of PDB ligands with drugs. Chemical properties of 5040 PDB ligands and 2396 drug molecules 
are compared: histograms for numbers of hydrogen bond donors and acceptors, logP value and molecular weight are shown. 
Molecular weight within [100,200) means that the molecular weight is greater than or equal to 100 and less than 200. Those 
areas for which the Lipinski "Rule of 5" is fulfilled, are highlighted in grey.
Table 1: Percentage of PDB ligands and drugs violating certain 
numbers of Lipinski Rules
Number of violated Lipinski Rules PDB ligands Drugs
06 4 . 4 7 5 . 7
11 6 . 9 1 4 . 0
21 0 . 3 5 . 7
3 8.3 4.7
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